Fresenius SE & Co. KGaA

Earnings Release • Feb 21, 2012

News Details

Ad-hoc | 21 February 2012 06:59

Fresenius SE & Co. KGaA: Fresenius achieves record sales and earnings in 2011- Strong growth expected in all business segments for 2012

Fresenius SE & Co. KGaA / Key word(s): Final Results

21.02.2012 06:59

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Fresenius achieves record sales and earnings in 2011-
Strong growth expected in all business segments for 2012

Group sales increased by 3% (6% in constant currency) to EUR16,522 million
(2010: EUR15,972 million). Organic sales growth was 4%. Acquisitions
contributed a further 2%. Currency translation had a negative effect of 3%.

Group EBIT increased by 6% (9% in constant currency) to EUR2,563 million
(2010: EUR2,418 million). EBIT margin improved by 40 basis points to 15.5%
(2010: 15.1%).

Group net income* increased by 17% (18% in constant currency) to EUR770
million (2010: EUR660 million). Earnings per share increased by 16% to
EUR4.73 (2010: EUR4.08).

Including special items, Group net income** reached EUR690 million or
EUR4.24 per share.

Based on the excellent financial results, the Management Board will propose
to the Supervisory Board a dividend increase of 10% to EUR0.95 per ordinary
share (2010: EUR0.86).

For 2012, Fresenius projects sales growth of 10-13% in constant
currency***. Net income* is expected to increase by 8% to 11% in constant
currency. This implies a 2010 through 2012 3-year CAGR (compounded annual
growth rate) of 8% to 9% for sales and 16% to 17% for net income.

The Group's U.S. GAAP financial results as of December 31, 2011 and as of
December 31, 2010 include the effects of mark-to-market accounting of the
Mandatory Exchangeable Bonds (MEB) and the Contingent Value Rights (CVR)
related to the acquisition of APP Pharmaceuticals Inc. Adjusted earnings
represent the Group's business operations in the reporting period.

* Net income attributable to Fresenius SE & Co. KGaA; adjusted for the
effects of mark-to-market accounting of the Mandatory Exchangeable Bonds
(MEB) and the Contingent Value Rights (CVR) related to the acquisition of
APP Pharmaceuticals. Both are non-cash items and occurred for the last time
in 2011.
** Net income attributable to Fresenius SE & Co. KGaA
*** Based on adjusted 2011 sales of EUR 16,361 million due to a U.S. GAAP
accounting change at Fresenius Medical Care.

(Financial statements according to U.S. GAAP)

Fresenius SE & Co. KGaA,
represented by Fresenius Management SE,
Board of Management

Bad Homburg v.d.H., February 21, 2012

End of note

21.02.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Germany
Phone: +49 (0)6172 608-2485
Fax: +49 (0)6172 608-2488
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.com
ISIN: DE0005785604
WKN: 578560
Indices: DAX
Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard),
München; Freiverkehr in Berlin, Hamburg, Hannover, Stuttgart;
Terminbörse EUREX

End of Announcement DGAP News-Service

---